BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25649538)

  • 1. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
    Mizuguchi T; Torigoe T; Satomi F; Shima H; Kutomi G; Ota S; Ishii M; Hayashi H; Asakura S; Hirohashi Y; Meguro M; Kimura Y; Nishidate T; Okita K; Ishino M; Miyamoto A; Hatakenaka M; Sato N; Hirata K
    Surg Today; 2016 Feb; 46(2):139-48. PubMed ID: 25649538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
    Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
    Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
    Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pancreatic cancer vaccines could unleash the army within.
    Springett GM
    Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
    Koido S; Okamoto M; Shimodaira S; Sugiyama H
    Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for pancreatic ductal adenocarcinoma.
    Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
    J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer: vaccine is safe and improves survival.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Mar; 12(3):128. PubMed ID: 25645600
    [No Abstract]   [Full Text] [Related]  

  • 8. Pancreatic cancer, treatment options, and GI-4000.
    Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
    Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
    Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
    J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
    Ota S; Miyashita M; Yamagishi Y; Ogasawara M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5563-5572. PubMed ID: 34919493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision immunology: the promise of immunotherapy for the treatment of cancer.
    Kaufman HL
    J Clin Oncol; 2015 Apr; 33(12):1315-7. PubMed ID: 25605852
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for pancreatic cancer.
    Soares KC; Zheng L; Edil B; Jaffee EM
    Cancer J; 2012; 18(6):642-52. PubMed ID: 23187853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
    Nishida S; Ishikawa T; Egawa S; Koido S; Yanagimoto H; Ishii J; Kanno Y; Kokura S; Yasuda H; Oba MS; Sato M; Morimoto S; Fujiki F; Eguchi H; Nagano H; Kumanogoh A; Unno M; Kon M; Shimada H; Ito K; Homma S; Oka Y; Morita S; Sugiyama H
    Cancer Immunol Res; 2018 Mar; 6(3):320-331. PubMed ID: 29358173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
    Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
    PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
    Garrido-Laguna I; Hidalgo M
    Nat Rev Clin Oncol; 2015 Jun; 12(6):319-34. PubMed ID: 25824606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
    Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
    Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
    Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
    Cheng X; Zhao G; Zhao Y
    Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.